Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Universe Pharmaceuticals INC

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

JI'AN, JIANGXI, CHINA, JUNE 26, 2026 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (NASDAQ: UPC) ("UNIVERSE PHARMACEUTICALS" OR THE "COMPANY"), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED THAT THE COMPANY HAS ENTERED INTO A SHARE PURCHASE AGREEMENT TO ACQUIRE 100% OF THE ISSUED SHARES OF BEST PRAISE INTERNATIONAL LIMITED ("BEST PRAISE"), A COMPANY THAT HOLDS FIVE PATENTS IN CHINA WITH POTENTIAL APPLICATIONS IN PHARMACEUTICAL DEVELOPMENT, FOR A TOTAL PURCHASE PRICE OF US$10,751,000, PAYABLE IN THE FORM OF 4,376,552 CLASS A ORDINARY SHARES OF THE COMPANY.

UNIVERSE PHARMACEUTICALS INC ANNOUNCES STRATEGIC ACQUISITION TO EXPAND PHARMACEUTICAL PATENT PORTFOLIO

MARLBOROUGH, MASS.--(BUSINESS WIRE)--HOLOGIC, INC. TODAY ANNOUNCED A SIGNIFICANT AND FAR-REACHING VICTORY IN THE UNIFIED PATENT COURT (UPC) IN GERMANY, WHICH RULED THAT SIEMENS* INFRINGED UPON A CRITICAL HOLOGIC MAMMOGRAPHY TECHNOLOGY PATENT IN SIEMENS' LATEST MAMMOGRAPHY SYSTEM. THE COURT IMPOSED A SWEEPING INJUNCTION, IMMEDIATELY PROHIBITING SIEMENS FROM MAKING, OFFERING, PLACING ON THE MARKET, USING OR IMPORTING OR STORING FOR THOSE PURPOSES ITS MAMMOMAT B.BRILLIANT SYSTEMS ACROSS GERMANY, F.

HOLOGIC SECURES SIGNIFICANT PATENT VICTORY AGAINST SIEMENS OVER BREAST CANCER DETECTION TECHNOLOGY

JI'AN, JIANGXI, CHINA, FEB. 11, 2026 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (NASDAQ: UPC) (UNIVERSE PHARMACEUTICALS OR THE COMPANY), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED THAT ALL CONDITIONS TO THE IMPLEMENTATION OF ITS DUAL-CLASS SHARE STRUCTURE HAVE BEEN SATISFIED AND THAT ITS DUAL-CLASS SHARE STRUCTURE WILL BECOME EFFECTIVE ON THE NASDAQ CAPITAL MARKET ON FEBRUARY 13, 2026.

UNIVERSE PHARMACEUTICALS INC ANNOUNCES EFFECTIVE DATE OF DUAL-CLASS SHARE STRUCTURE

JIANGXI, CHINA, MARCH 20, 2025 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (NASDAQ: UPC) (UNIVERSE PHARMACEUTICALS OR THE COMPANY), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED THAT THE COMPANY PLANS TO EFFECT A SHARE CONSOLIDATION OF 40 ORDINARY SHARES WITH PAR VALUE OF US$0.28125 PER SHARE EACH IN THE COMPANY'S ISSUED AND UNISSUED SHARE CAPITAL INTO ONE (1) ORDINARY SHARE WITH PAR VALUE OF US$11.25 (THE SHARE CONSOLIDATION). AS A RESULT OF THE SHARE CONSOLIDATION, EACH 40 PRE-CONSOLIDATION ORDINARY SHARES OUTSTANDING WILL AUTOMATICALLY COMBINE AND CONVERT TO ONE ISSUED AND OUTSTANDING ORDINARY SHARE WITHOUT ANY ACTION ON THE PART OF THE SHAREHOLDERS.

UNIVERSE PHARMACEUTICALS INC ANNOUNCES SHARE CONSOLIDATION

JI'AN, JIANGXI, CHINA, FEB. 25, 2025 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (THE COMPANY) (NASDAQ: UPC), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED THAT ON FEBRUARY 19, 2025, THE COMPANY RECEIVED A STAFF DETERMINATION NOTICE FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ), NOTIFYING THE COMPANY THAT IT IS DELINQUENT IN FILING ITS ANNUAL REPORT ON FORM 20-F FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2024 (THE FORM 20-F) AND THAT THIS MATTER SERVES AS AN ADDITIONAL BASIS FOR DELISTING THE COMPANY'S SECURITIES FROM NASDAQ. THE FAILURE TO TIMELY FILE THE FORM 20-F IS A VIOLATION OF NASDAQ LISTING RULE 5250(C)(1).

UNIVERSE PHARMACEUTICALS INC RECEIVES STAFF DETERMINATION NOTICE FROM NASDAQ RELATED TO DELAYED ANNUAL REPORT

JI'AN, JIANGXI, CHINA, FEB. 03, 2025 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (THE COMPANY) (NASDAQ: UPC), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED THAT THE COMPANY RECEIVED A LETTER FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) ON JANUARY 29, 2025, NOTIFYING THE COMPANY THAT THE NASDAQ STAFF HAS DETERMINED TO DELIST THE COMPANY'S ORDINARY SHARES FROM THE NASDAQ CAPITAL MARKET (THE DELISTING DETERMINATION), BECAUSE THE BID PRICE OF THE COMPANY'S LISTED SECURITIES HAS CLOSED AT LESS THAN $1 PER SHARE OVER THE PREVIOUS 30 CONSECUTIVE BUSINESS DAYS, AND THEREFORE NO LONGER COMPLIES WITH THE NASDAQ LISTING RULE 5550(A)(2) (THE RULE). NORMALLY, A COMPANY WOULD BE AFFORDED A 180-CALENDAR DAY PERIOD TO DEMONSTRATE COMPLIANCE WITH THE RULE. HOWEVER, PURSUANT TO THE NASDAQ LISTING RULE 5810(C)(3)(A)(IV), THE COMPANY IS NOT ELIGIBLE FOR ANY COMPLIANCE PERIOD SPECIFIED IN NASDAQ LISTING RULE 5810(C)(3)(A) DUE TO THE FACT THAT THE COMPANY EFFECTED A REVERSE STOCK SPLIT ON NOVEMBER 18, 2024, OR WITHIN THE PRIOR ONE-YEAR PERIOD.

UNIVERSE PHARMACEUTICALS INC RECEIVES NASDAQ DELISTING NOTICE SUBJECT TO HEARING REQUEST

NEW YORK, DEC. 10, 2024 (GLOBE NEWSWIRE) -- UNIVEST SECURITIES, LLC (UNIVEST), A MEMBER OF FINRA AND SIPC, AND A FULL-SERVICE INVESTMENT BANK AND SECURITIES BROKER-DEALER FIRM BASED IN NEW YORK, TODAY ANNOUNCED THE CLOSING OF REGISTERED DIRECT OFFERING (THE OFFERING) OF ITS CLIENTUNIVERSE PHARMACEUTICALS INC (NASDAQ: UPC) (THE COMPANY), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA.

UNIVEST SECURITIES, LLC ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING FOR ITS CLIENT UNIVERSE PHARMACEUTICALS INC (NASDAQ: UPC)

JI'AN, JIANGXI, CHINA, NOV. 01, 2024 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (THE COMPANY) (NASDAQ: UPC), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED THAT THE COMPANY RECEIVED A WRITTEN NOTIFICATION (THE "NOTIFICATION LETTER") FROM THE NASDAQ STOCK MARKET LLC ("NASDAQ") ON OCTOBER 25, 2024, NOTIFYING THE COMPANY THAT IT IS NOT IN COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT SET FORTH IN THE NASDAQ LISTING RULES FOR CONTINUED LISTING ON THE NASDAQ.

UNIVERSE PHARMACEUTICALS INC RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY

JI'AN, JIANGXI, CHINA, SEPT. 20, 2024 (GLOBE NEWSWIRE) -- UNIVERSE PHARMACEUTICALS INC (THE COMPANY, WE, OUR AND US) (NASDAQ: UPC), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE FIRST SIX MONTHS OF FISCAL YEAR 2024 ENDED MARCH 31, 2024.

UNIVERSE PHARMACEUTICALS INC REPORTS FINANCIAL RESULTS FOR THE FIRST SIX MONTHS OF FISCAL YEAR 2024

JI'AN,CHINA, JAN. 30, 2024 /PRNEWSWIRE/ -- UNIVERSE PHARMACEUTICALS INC ("UNIVERSE PHARMACEUTICALS" OR THE "COMPANY") (NASDAQ: UPC), A PHARMACEUTICAL PRODUCER AND DISTRIBUTOR IN CHINA, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2023. MR. GANG LAI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF UNIVERSE PHARMACEUTICALS, COMMENTED, "DESPITE MARKET FLUCTUATIONS AND THE ECONOMIC SLOWDOWN IMPACTING OUR BUSINESS IN FISCAL YEAR 2023, WE CONTINUED OUR EFFORTS TO DELIVER HIGH QUALITY PRODUCTS TO OUR LOYAL CUSTOMERS.

Universe Pharmaceuticals INC

UPC

Price

Financial Reports

No items found.

Press Releases

Universe Pharmaceuticals INC

UPC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

UPC